This variant is absent from gnomAD v2.1 and gnomAD-Canada, and present at extremely low frequency in gnomAD v4.1 (AF=0.000124%, 2/1,614,084 alleles, 0 homozygotes), meeting PM2 at supporting strength.¹ Multiple in silico tools predict no damaging effect: REVEL score 0.266, BayesDel score 0.181, and SpliceAI max delta 0.00, meeting BP4 at supporting benign strength.² The variant has been reported in ClinVar as Uncertain significance by five clinical laboratories (Variation ID: 574602). No expert panel review or pathogenic/benign classification has been rendered.³ No variant-specific functional studies, cosegregation data, de novo observations, or case-control enrichment data are available. OncoKB reports Unknown Oncogenic Effect with no curated functional evidence.⁴ The opposing PM2 (supporting) and BP4 (supporting benign) criteria effectively cancel each other, yielding an evidence framework consistent with Uncertain significance.